GenoMed Retains E & E Communications to Assist Investor and Public Relations Programs
Thursday March 4, 6:00 am ET
ST. LOUIS, March 4 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, today announced that it has retained E & E Communications, Orange County, California, ( eandecommunications.com ) to assist its public relations and investor relations programs.
ADVERTISEMENT
GenoMed is a leader in the medical revolution which has been made possible by medical genomics. It has proven its ability to improve patient outcomes by identifying the genetic pathways that cause disease.
"Our ability to prevent end-stage kidney disease from diabetes and high blood pressure, and our novel approach to viral diseases, including SARS, avian influenza, and West Nile virus encephalitis, deserve widespread dissemination to the public and to investors. We are pleased to be stepping up our efforts to tell the GenoMed story," said Dr. David Moskowitz, Chairman, CEO and Chief Medical Officer.
"Dr. Moskowitz' extraordinary background, including his education at Harvard and Oxford and his groundbreaking research and clinical efforts in treating kidney disease and West Nile virus, plus his pioneer work in medical genomics, make this an extraordinary company," said Paul Knopick, Principal, E & E Communications. E & E Communications, formed in 1997, serves firms on the NASDAQ National Market and Small Cap, AMEX, Toronto Stock Exchange and OTC BB companies that are fully reporting to the U.S. Securities & Exchange Commission. "We are pleased with the opportunity to introduce GenoMed to the media and investors."
biz.yahoo.com |
